Association study of the interieukin-Ibeta (C-5I IT) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response

Neuropsychopharmacology

Volumn 28, Issue 6, 2003, Pages 1182-1185

  Yu, Younger W Y ^a   Chen, Tai Jui ^b   Hong, Chen Jee ^c,d   Chen, Hung Mei ^c   Tsai, Shih Jen ^c,d  

^a Yu's Psychiatric Clinic   (Taiwan)

^b Kai Suan Psychiatric Hospital   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Interleukin Ibeta; Major depressive disorders; Polymorphism; Selective serotonin reuptake inhibitors; Treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; INTERLEUKIN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 0042844775     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300172     Document Type: Article

References (25)

1. Anisman H, Ravindran AV, Griffiths J, Merali Z (1999).Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry4: 182-188.
2. Brambilla F, Maggioni M (1998). Blood levels of cytokines in elderly patients with major depressive disorder. ActaPsychiatr97: 309-313.
3. Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J ClinOncol18: 2143-2151.
4. Castanon N, Bluthe RM, Dantzer R (2001). Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysacchar-ide and interleukin-1beta in the rat. Psychopharmacologia154: 50-60.
5. Connor TJ, Leonard BE (1998). Depression, stress and immuno-logical activation: the role of cytokines in depressive disorders. Life Sci62: 583-606.
6. Dantzer R, Wollman E, Vitkovic L, Yirmiya R (1999). Cytokines and depression: fortuitous or causative association?Mol Psychiatry4: 328-332.
7. Elsehety A, Bertorini TE (1997). Neurologic and neuropsychiatric complications of Crohn’s disease. South Med J90: 606-610.
8. Hamilton M (1967).Development of a rating scale for primary depressive illness. Br J SocClinPsychol6: 278-296.
9. Kagaya A, Kugaya A, Takebayashi M, Fukue-Saeki M, Saeki T, Yamawaki S (2001). Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology43: 59-62.
10. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000).Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology22: 370-379.
11. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V (1999). Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology40: 171-176.
12. Licinio J, Wong ML (1999). The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry4: 317-327.
13. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R (1995). Increased plasma concentrations of inter-leukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord34: 301-309.
14. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J (1993).Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res49: 11-27.
15. Maier SF, Watkins LR (1995). Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear condition-ing and interference with escape produced by inescapable shock. Brain Res695: 279-282.
16. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG (1994). Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology106: 637-642.
17. Muller N, Ackenheil M (1998). Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry22: 1-33.
18. Nelson KP, Marks NL, Heyen JR, Johnson RW (1999). Behavior of adult and aged mice before and after central injection of interleukin-1beta. PhysiolBehav66: 673-679.
19. Owen BM, Eccleston D, Ferrier IN, Young AH (2001).Raised levels of plasma interleukin-1beta in major and postviral depression. ActaPsychiatrScand103: 226-228.
20. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992). A Taql polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest22: 396-402.
21. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A (2001). Inflammatory markers in major depression and melancholia. J Affect Disord63: 93-102.
22. Utset TO, Golden M, Siberry G, Kiri N, Crum RM, Petri M (1994). Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren’s syndrome. J Rheumatol21: 2039-2045.
23. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H (1994).Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry35: 42-47.
24. Winokur G (1997). All roads lead to depression: clinically homoge-neous, etiologically heterogeneous. J Affect Disord45: 97-108.
25. Yu YWY, Tsai SJ, Chen TJ, Lin CH, Hong CJ (2002). Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry7: 1115-1119.